Biohaven (BHVN) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BHVN shares.
View BHVN analyst ratings or view top-rated stocks.

7 analysts have issued 1-year price objectives for Biohaven's stock. Their BHVN share price forecasts range from $21.00 to $148.50. On average, they anticipate the company's share price to reach $38.39 in the next twelve months. This suggests a possible upside of 119.0% from the stock's current price.
View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts.

Biohaven's stock was trading at $13.88 at the beginning of the year. Since then, BHVN stock has increased by 26.3% and is now trading at $17.53.
View the best growth stocks for 2023 here.

Biohaven saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 7,010,000 shares, an increase of 5.1% from the April 15th total of 6,670,000 shares. Based on an average daily volume of 883,100 shares, the short-interest ratio is currently 7.9 days. Currently, 12.1% of the company's stock are short sold.
View Biohaven's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our BHVN earnings forecast.

Biohaven Ltd. (NYSE:BHVN) posted its quarterly earnings results on Thursday, March, 23rd. The company reported ($3.32) earnings per share for the quarter, missing the consensus estimate of ($1.24) by $2.08.

ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Vanguard Russell 2000 Growth ETF (VTWG), Vanguard Russell 2000 Value ETF (VTWV), Inspire Global Hope ETF (BLES) and Principal Healthcare Innovators ETF (BTEC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Biohaven trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Biohaven's stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (6.67%), BlackRock Inc. (6.32%), FMR LLC (5.36%), Armistice Capital LLC (4.58%), Price T Rowe Associates Inc. MD (2.41%) and Pictet Asset Management SA (1.77%). Insiders that own company stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Matthew Buten, Robert Berman, Vlad Coric and William A Jones Jr.
View institutional ownership trends.

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BHVN stock can currently be purchased for approximately $17.53.

Biohaven (NYSE:BHVN) has a market capitalization of $1.20 billion and generates $462.51 million in revenue each year. The company earns $-570,280,000.00 in net income (profit) each year or ($12.31) on an earnings per share basis.

The company employs 928 workers across the globe.

Biohaven's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via phone at 203-404-0410 or via email at jennifer.porcelli@biohavenpharma.com.